These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37606127)

  • 1. Is tirzepatide 15 mg the preferred treatment strategy for type 2 diabetes? A meta-analysis and trial-sequence-analysis.
    Yang XY; Yin S; Yu YF; Hu G; Hang FZ; Zhou ML; Liu P; Jian WX
    Eur Rev Med Pharmacol Sci; 2023 Aug; 27(15):7164-7179. PubMed ID: 37606127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.
    Karagiannis T; Avgerinos I; Liakos A; Del Prato S; Matthews DR; Tsapas A; Bekiari E
    Diabetologia; 2022 Aug; 65(8):1251-1261. PubMed ID: 35579691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal dose of tirzepatide for type 2 diabetes mellitus: A meta-analysis and trial sequential analysis.
    Yu Y; Hu G; Yin S; Yang X; Zhou M; Jian W
    Front Cardiovasc Med; 2022; 9():990182. PubMed ID: 36119737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastrointestinal adverse events of tirzepatide in the treatment of type 2 diabetes mellitus: A meta-analysis and trials sequential analysis.
    Tong K; Yin S; Yu Y; Yang X; Hu G; Zhang F; Liu Z
    Medicine (Baltimore); 2023 Oct; 102(43):e35488. PubMed ID: 37904345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.
    Nauck MA; D'Alessio DA
    Cardiovasc Diabetol; 2022 Sep; 21(1):169. PubMed ID: 36050763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is polyethylene glycol loxenatide 100 μg the preferred glucagon-like peptide-1 receptor agonist for type 2 diabetes mellitus? A meta-analysis and trial sequential analysis.
    Liu P; Yu YF; Jiang PF; Yang XY; Tong KK; Hu G; Yin S; Yu R
    Eur Rev Med Pharmacol Sci; 2024 Mar; 28(6):2272-2287. PubMed ID: 38567590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide.
    Nauck MA; Mirna AEA; Quast DR
    Diabetes Obes Metab; 2023 May; 25(5):1361-1371. PubMed ID: 36700380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of dorzagliatin for type 2 diabetes mellitus: A meta-analysis and trial sequential analysis.
    Yu Y; Yang X; Tong K; Yin S; Hu G; Zhang F; Jiang P; Zhou M; Jian W
    Front Cardiovasc Med; 2022; 9():1041044. PubMed ID: 36505359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice.
    Bradley CL; McMillin SM; Hwang AY; Sherrill CH
    Ann Pharmacother; 2023 Jul; 57(7):822-836. PubMed ID: 36367094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
    Heise T; Mari A; DeVries JH; Urva S; Li J; Pratt EJ; Coskun T; Thomas MK; Mather KJ; Haupt A; Milicevic Z
    Lancet Diabetes Endocrinol; 2022 Jun; 10(6):418-429. PubMed ID: 35468322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis.
    Tan B; Pan XH; Chew HSJ; Goh RSJ; Lin C; Anand VV; Lee ECZ; Chan KE; Kong G; Ong CEY; Chung HC; Young DY; Chan MY; Khoo CM; Mehta A; Muthiah MD; Noureddin M; Ng CH; Chew NWS; Chin YH
    Int J Obes (Lond); 2023 Aug; 47(8):677-685. PubMed ID: 37253796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse Events Related to Tirzepatide.
    Mishra R; Raj R; Elshimy G; Zapata I; Kannan L; Majety P; Edem D; Correa R
    J Endocr Soc; 2023 Feb; 7(4):bvad016. PubMed ID: 36789109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes.
    Thomas MK; Nikooienejad A; Bray R; Cui X; Wilson J; Duffin K; Milicevic Z; Haupt A; Robins DA
    J Clin Endocrinol Metab; 2021 Jan; 106(2):388-396. PubMed ID: 33236115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
    Ludvik B; Giorgino F; Jódar E; Frias JP; Fernández Landó L; Brown K; Bray R; Rodríguez Á
    Lancet; 2021 Aug; 398(10300):583-598. PubMed ID: 34370970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tirzepatide in Hispanic/Latino Patients With Type 2 Diabetes: A Subgroup Analysis of the SURPASS Program.
    Frías JP; Galindo RJ; Wang H; Malik RE; Chivukula KK; Maldonado JM
    J Clin Endocrinol Metab; 2024 Jan; 109(2):557-568. PubMed ID: 37602701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials.
    Patel H; Khunti K; Rodbard HW; Bajaj HS; Bray R; Kindracki Z; Rodríguez Á
    Diabetes Obes Metab; 2024 Feb; 26(2):473-481. PubMed ID: 37853960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies.
    Lingvay I; Cheng AY; Levine JA; Gomez-Valderas E; Allen SE; Ranta K; Torcello-Gómez A; Thieu VT
    Diabetes Obes Metab; 2023 Apr; 25(4):965-974. PubMed ID: 36514843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
    Rosenstock J; Wysham C; Frías JP; Kaneko S; Lee CJ; Fernández Landó L; Mao H; Cui X; Karanikas CA; Thieu VT
    Lancet; 2021 Jul; 398(10295):143-155. PubMed ID: 34186022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
    Dahl D; Onishi Y; Norwood P; Huh R; Bray R; Patel H; Rodríguez Á
    JAMA; 2022 Feb; 327(6):534-545. PubMed ID: 35133415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the Efficacy and Safety of Tirzepatide on Glycaemic and Non-glycaemic Outcomes in Diabetes: A Systematic Review of Meta-Analyses.
    Kaore S; B B; Khasbage S; Atal S
    Cureus; 2024 Mar; 16(3):e56939. PubMed ID: 38665722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.